2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 659

IL-17 Producing T Cells and Its Dichotomy: A Mixed Response of the Innate and Acquired Immune System in Psoriatic Arthritis
Abstract Number: 660

Strain-Dependent IL-17A Secretion By CD4-CD8- DN αβ T Cells Correlates with Disease Susceptibility in Murine Spondyloarthritis
Abstract Number: 661

Normal Human Enthesis Contains a Resident Population of γδT-Cells
Abstract Number: 662

Clinical Significance of Non-Albumin Proteinuria for Severity Assessment of Tubulointerstitial Inflammation in Lupus Nephritis
Abstract Number: 663

Urinary Tumor-Necrosis Factor-like Weak Inducer of Apoptosis Is an Important Biomarker for Renal Lupus
Abstract Number: 664

Low Vitamin D Is Associated with Thrombosis in Systemic Lupus Erythematosus
Abstract Number: 665

Low Vitamin D Is Associated with End Stage Renal Disease in Systemic Lupus Erythematosus
Abstract Number: 666

Vitamin D Deficiency Is Associated with Increased Serum Cholesterol Among Patients with Systemic Lupus Erythematosus
Abstract Number: 667

Urinary Metabolomic Fingerprint As Diagnostic Biomarker for Clinical Significant Lupus Nephritis
Abstract Number: 668

Is Uric Acid Level a Predictor of Long-Term Renal Outcome in Lupus Nephritis?
Abstract Number: 669

Unbiased Screening of Urinary Protein Biomarkers for Glomerular Filtration Rate Normalization
Abstract Number: 670

Membrane Attack Complex (MAC) Deposition in Lupus Nephritis Is Associated with Hypertension and Poor Clinical Response to Treatment
Abstract Number: 671

A New Histological Index for Predicting a Decline in Kidney Function in Patients with Lupus Nephritis. a Mexican Cohort Study of 186 Patients with a Kidney Biopsy
Abstract Number: 672

Baseline Hyperuricemia As a Predictive Value for Development of Lupus Nephritis in Premenopausal SLE Patients
Abstract Number: 673

Cell Bound Complement Activation Products Distinguish Systemic Lupus Erythematosus from Other Diseases Among Patients with High Antinuclear Antibody Titers and Normal Complement

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].